Keywords
Fields of Research (FoR)
Genetic Immunology, GenomicsSEO tags
Biography
Professor Chris Goodnow FAA FRS is Executive Director of the Garvan Institute of Medical Research, holds The Bill and Patricia Ritchie Foundation Chair as Head of the Immunogenomics Laboratory at Garvan, and is Professor and Director of the Cellular Genomics Futures Institute at UNSW Sydney. Chris trained in veterinary medicine and surgery, immunochemistry, and immunology at the University of Sydney and in DNA technology and molecular...view more
Professor Chris Goodnow FAA FRS is Executive Director of the Garvan Institute of Medical Research, holds The Bill and Patricia Ritchie Foundation Chair as Head of the Immunogenomics Laboratory at Garvan, and is Professor and Director of the Cellular Genomics Futures Institute at UNSW Sydney. Chris trained in veterinary medicine and surgery, immunochemistry, and immunology at the University of Sydney and in DNA technology and molecular immunology at Stanford University. Chris is internationally recognised for discovering and establishing the concept of sequential tolerance checkpoints to prevent the immune system attacking “self” while fighting off “foreign” infections, laying the scientific foundation for the recent success of checkpoint inhibitor drugs to activate immune destruction of “self” cancer cells. He pioneered the use of mammalian genome sequencing to reveal how the body’s phenotype results from its’ genotype – “phenomics”. Most recently his team have used single cell genomics to discover that rogue immune cells bypass tolerance checkpoints to cause autoimmune disease through mutation pathways that also cause lymphoma and leukemia. Chris’ many awards include the AAI Pharmingen Award, Gottschalk Medal, Health Minister’s Prize, Centenary Medal, Ramaciotti Medal, GSK Award for Research Excellence, William E. Paul Award, Fellow of the Australian Academy of Science, Fellow of the Royal Society, and Member of the US National Academy of Sciences.
My Qualifications
BVSc Hons 1; BSc(Vet) Hons 1 & University Medal; PhD
My Awards
1984 |
Honours Class I with B.V.Sc. degree; |
1986 |
NH & MRC Biomedical Research Scholarship |
1989 |
Medical Foundation Postdoctoral Fellowship |
1990 |
Investigator of the Howard Hughes Medical Institute |
1992 |
Searle Scholar |
1998 |
American Association of Immunologists Pharmingen Investigator Award |
2001 |
Gottschalk Medal, Australian Academy of Science |
2002 |
Fellow of the Australian Academy of Science |
2005 |
Health Minister’s Prize for Excellence in Medical Research |
2005 |
ISI Highly Cited Researcher |
2006 |
Centenary Medal |
2006 |
ARC Federation Fellow |
2007 |
Ramaciotti Major Research Award |
2009 |
Fellow of the Royal Society |
2010 |
NHMRC Australia Fellow |
2010 |
The Ramaciotti Medal |
2012 |
Glaxo-Smith-Kline Award for Research Excellence |
2013 |
Member of the US National Academy of Science |
2018 |
William E Paul Memorial Award, The Foundation for Primary Immune Diseases. |
My Research Supervision
Areas of supervision
Project: Using genomic technology to study the rogue cells that cause autoimmune disease
Discipline: Immunology
Project level: PhD/Honours
Supervisor: Prof Chris Goodnow & Dr Joanne Reed
Project commencement: Variable
Summary: Autoimmune disease occurs when immune cells "go rogue" and attack healthy parts of the body, instead of attacking infectious microbes. There are over 100 different autoimmune diseases, which affects 5-10% of the population and are a major cause of chronic disease in our society. Without a cure, individuals afflicted by these diseases face ongoing clinical care based on suppressing the whole immune system. Current clinical practice treats the symptoms of disease rather than the cause because we don't have a way to identify and eradicate the individual cells of the immune system that have gone rogue. Our group has developed innovative cellular genomics technology incorporating single cell sequencing and multi-parameter flow cytometry to identify and isolate rogue B cells from patients with the autoimmune diseases Sjogren's syndrome and lupus. This research has uncovered therapeutic targets and allowed us to trace the evolution of these disease causing cells.
We are currently recruiting enthusiastic students who are interested in using cutting-edge genomic technology to learn about fundamental mechanisms of the immune system and impact treatment strategies and outcomes in patients with autoimmune diseases.
Contact: Dr Joanne Reed at j.reed@garvan.org.au
Location
384 Victoria Street
Darlinghurst NSW 2010
Map reference (Google map)